AURKA and triple-negative breast carcinoma: In this study, we analyzed the role of PFDN4 in breast cancer using the TCGA database and investigated the effect of chemotherapeutic agents via the CREBP1/AURKA pathway in triple-negative breast cancer, leading to the recent discovery that PFDN4 could serve as a potential biomarker for prognosis and chemotherapy resistance.